Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) reached 31.38% versus a 1-year low price of $2.39. The stock was last seen 9.03% higher, reaching at $3.14 on 01/10/2019. At recent session, the prices were hovering between $2.78 and $3.18. This company shares are 174.84% off its target price of $8.63 and the current market capitalization stands at $179.86M. The recent change has given its price a -5.34% deficit over SMA 50 and -67.79% deficit over its 52-week high. The stock witnessed -8.99% declines, -36.82% declines and -40.3% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found PIRS’s volatility during a week at 7.44% and during a month it has been found around 10.11%.Pieris Pharmaceuticals, Inc. (PIRS) Top Holders
Institutional investors currently hold around $102 million or 67.3% in PIRS stock. Look at its top three institutional owners. Bvf Inc/Il owns $16.13 million in Pieris Pharmaceuticals, Inc., which represents roughly 8.97% of the company’s market cap and approximately 15.81% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 2,687,508 shares of the stock are valued at $7.74 million. The third largest holder is Orbimed Advisors Llc, which currently holds $7.07 million worth of this stock and that ownership represents nearly 3.93% of its market capitalization.Pieris Pharmaceuticals, Inc. 13F Filings
At the end of September reporting period, 53 institutional holders increased their position in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) by some 3,532,536 shares, 53 decreased positions by 3,138,904 and 22 held positions by 28,804,461. That puts total institutional holdings at 35,475,901 shares, according to SEC filings. The stock grabbed 13 new institutional investments totaling 1,123,163 shares while 23 institutional investors sold out their entire positions totaling 665,351 shares.Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Insider Trades
Multiple company employees have indulged in significant insider trading. Pieris Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Kiritsy Christopher P has acquired 5,000 shares of Pieris Pharmaceuticals, Inc. (PIRS) in trading session dated Sep. 14, 2018. These shares are worth $25,550 and were traded at $5.11 each. The SEC filing shows that Geraghty James A performed a purchase of 10,000 shares. The Director added these shares by way of transaction on May. 15, 2018. The company’s shares were assimilated at $5.75 per share worth to an investment of some $57,500 on account of Geraghty James A.
, Orbimed Advisors Llc, sold 1,000,000 common shares of Pieris Pharmaceuticals, Inc. (PIRS) in the open market. In a transaction dated Apr. 30, 2018, the shares were put up for sale at an average price of $6.35, raking in a sum of $6,350,000. After this sale, 38,870 common shares of PIRS are directly owned by the insider, with total stake valued at $122,052.
In the transaction dated Feb. 13, 2018, the great number of shares disposed came courtesy the 10% Owner; Orbimed Advisors Llc disposed a total of 7,897 shares at an average price of $8.98, amounting to approximately $70,915. The insider now directly owns 49,270 shares worth $154,708.Pieris Pharmaceuticals, Inc. (PIRS) Analyst Guide
Several analysts have released their opinion on Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.5 average brokerage recommendation.